Introduction During the current COVID-19 pandemic, there has been increased interest in using off-label medications for treatment of the novel coronavirus (SARS-CoV-2), including drugs with a propensity for QT prolongation such as hydroxychloroquine and azithromycin.(1) to evaluate and manage the QT interval in patients undergoing therapy Materials and methods: A prospective study of 156 Covid patients In all department of the Mohammed VI university hospital in Marrakech during the period from 1 April 2020 to 15 April 2020. Résultats: Conclusion: Les thérapies pour COVID-19 peuvent entraîner des effets indésirables cardio- vasculaires à la phase aiguë potentiellement graves et nécessitant une surveillance rapprochée surtout de l interval QT par l electrocardiogramme.